AstraZeneca PLC (AZN)
77.20
-0.41
(-0.53%)
USD |
NASDAQ |
May 10, 16:00
77.20
0.00 (0.00%)
After-Hours: 20:00
AstraZeneca Research and Development Expense (Quarterly): 2.783B for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.783B |
| December 31, 2023 | 3.073B |
| September 30, 2023 | 2.584B |
| June 30, 2023 | 2.667B |
| March 31, 2023 | 2.611B |
| December 31, 2022 | 2.625B |
| September 30, 2022 | 2.458B |
| June 30, 2022 | 2.546B |
| March 31, 2022 | 2.133B |
| December 31, 2021 | 2.584B |
| September 30, 2021 | 3.61B |
| June 30, 2021 | 1.829B |
| March 31, 2021 | 1.713B |
| December 31, 2020 | 1.719B |
| September 30, 2020 | 1.495B |
| June 30, 2020 | 1.389B |
| March 31, 2020 | 1.388B |
| December 31, 2019 | 2.091B |
| September 30, 2019 | 1.346B |
| June 30, 2019 | 1.356B |
| March 31, 2019 | 1.266B |
| December 31, 2018 | 2.107B |
| September 30, 2018 | 1.242B |
| June 30, 2018 | 1.362B |
| March 31, 2018 | 1.279B |
| Date | Value |
|---|---|
| December 31, 2017 | 1.551B |
| September 30, 2017 | 1.404B |
| June 30, 2017 | 1.349B |
| March 31, 2017 | 1.453B |
| December 31, 2016 | 1.543B |
| September 30, 2016 | 1.402B |
| June 30, 2016 | 1.465B |
| March 31, 2016 | 1.48B |
| December 31, 2015 | 1.746B |
| September 30, 2015 | 1.429B |
| June 30, 2015 | 1.466B |
| March 31, 2015 | 1.356B |
| December 31, 2014 | 1.499B |
| September 30, 2014 | 1.552B |
| June 30, 2014 | 1.328B |
| March 31, 2014 | 1.20B |
| December 31, 2013 | 1.429B |
| September 30, 2013 | 858.00M |
| June 30, 2013 | 1.275B |
| March 31, 2013 | 1.259B |
| December 31, 2012 | 1.32B |
| September 30, 2012 | 1.204B |
| June 30, 2012 | 1.189B |
| March 31, 2012 | 1.53B |
| December 31, 2011 | 1.867B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.346B
Minimum
Sep 2019
3.61B
Maximum
Sep 2021
2.20B
Average
2.296B
Median
Research and Development Expense (Quarterly) Benchmarks
| GSK PLC | 1.819B |
| Amgen Inc | 1.343B |
| Sanofi SA | 1.867B |
| Viking Therapeutics Inc | 24.10M |
| Fusion Pharmaceuticals Inc | 20.65M |